Form 4: GeneDx CFO Sells Shares for Tax Obligations

GeneDx Holdings Corp.'s Chief Financial Officer, Kevin Feeley, sold 1,266 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

Summary

• Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp., reported transactions on December 9, 2025.
• He acquired 2,462 shares of Class A Common Stock through the settlement of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, he sold 1,266 shares of Class A Common Stock at $159.28 per share.
• The sale was explicitly a 'sell to cover' transaction to satisfy tax withholding obligations and not a discretionary sale.
• Following these transactions, Feeley directly owns 5,389 shares of Class A Common Stock.
• He also beneficially owns RSUs representing contingent rights to receive up to 120,701 shares and options to purchase up to 25,906 shares, which vest according to their respective terms.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a sale of shares, it's explicitly for tax purposes related to RSU vesting, which is a positive sign of executive compensation and retention. The executive still holds a significant number of RSUs and options.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued compensation and retention of a key executive.
• The acquisition of 2,462 shares through RSU settlement increases the CFO's direct equity interest before the tax-related sale.

Negatives

• The sale of 1,266 shares, even for tax purposes, reduces the CFO's direct beneficial ownership of Class A Common Stock.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide broader industry context. It reflects standard equity compensation practices within publicly traded companies, particularly in the biotech/genomics sector where GeneDx operates.

Comparison to Industry Standards

• This is a standard 'sell to cover' transaction, a common practice for executives to manage tax liabilities arising from equity compensation vesting.
• It aligns with typical corporate governance and compensation practices in the U.S. public markets, where executives often sell a portion of vested shares to cover taxes without it being considered a discretionary sale reflecting a change in sentiment.

Related Party Transactions

• The transaction involves an executive and the company's stock, which is a related party transaction by definition, but it is a standard compensation-related event. No unusual related party dealings are disclosed beyond the equity compensation.

Stakeholder Impact

• Shareholders: A minor dilution effect from RSU settlement, offset by the 'sell to cover' which is a common practice. The CFO's continued equity holdings (RSUs and options) align his interests with shareholders.
• Management: The CFO continues to hold significant equity, indicating ongoing alignment with company performance.

Next Steps

• Remaining RSUs and options will vest according to their respective terms.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell to cover' transaction by the CFO to satisfy tax obligations upon RSU vesting. Such transactions are common and generally do not indicate a change in management's confidence or the company's fundamentals. The CFO still retains a substantial amount of unvested equity (RSUs and options), aligning his interests with long-term shareholder value. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it provides no new fundamental information to alter an existing investment thesis.

Keywords

GeneDx Holdings Corp., WGS, Form 4, Insider Trading, CFO, Kevin Feeley, Restricted Stock Units, RSU, Stock Sale, Tax Withholding, Equity Compensation